SGMO Stock Analysis: Buy, Sell, or Hold?
SGMO - Sangamo Therapeutics, Inc. Common Stock
$0.14
0.02 (13.26%)
▲
5d:
-28.98%
30d:
-48.1%
90d:
-74.79%
WAIT
LOW Confidence
Analysis Updated: May 1, 2026 12:00 AM ET
Earnings: May 11, 2026
7d
Get Alerted When SGMO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SGMO is down 29.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SGMO is down 29.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SGMO is currently trading at $0.14, which is considered oversold relative to its 30-day fair value range of $0.20 to $0.32.
Technical Outlook: Technically, SGMO is in a downtrend. Immediate support is located at $0.12, while resistance sits at $0.28. The stock is showing strong short-term momentum, up 13.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.75 (+2677.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SGMO is in a downtrend. Immediate support is located at $0.12, while resistance sits at $0.28. The stock is showing strong short-term momentum, up 13.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.75 (+2677.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.20 -
$0.32
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.3%)
- BULLISH: Trading 2677.8% below Wall St target ($3.75)
- WARNING: Recommendation downgraded due to -29.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.20 -
$0.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.12
Resistance Level
$0.28
Current Trend
Downtrend
Technical data as of
May 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.39
Wall Street Target
$3.75
(+2677.8%)
Revenue Growth (YoY)
88.4%
Share & Embed Analysis
Last updated: May 03, 2026 12:15 PM ET
Data refreshes hourly during market hours. Next update: 1:15 PM
Data refreshes hourly during market hours. Next update: 1:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SGMO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Gregory D Davis
SELL
69827 shares
2026-04-22
Nathalie Dubois-Stringfe…
SELL
345942 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 62 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 54 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 62 BUY |
